A Phase III Randomized Controlled Clinical Study of BL-M07D1 for Injection Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (G/GEJ) Adenocarcinoma After Failure of First-line Anti-HER2 Therapy
Latest Information Update: 20 Nov 2025
At a glance
- Drugs BL-M07D1 (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 17 Nov 2025 Status changed from not yet recruiting to recruiting.
- 12 Sep 2025 New trial record